Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.

Monami M, Zannoni S, Pala L, Silverii A, Andreozzi F, Sesti G, Mannucci E

International journal of cardiology5 May 2017Cited by 34 (Europe PMC)

PMID28501352DOI10.1016/j.ijcard.2017.03.163PepBankPUB-28501352

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) lowered all-cause mortality versus comparators.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, were linked to fewer deaths from any cause than comparators.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist comparators
Outcome group
Mortality · Cardiovascular
Measurements
MH-OR
0.88 ratio
all-cause mortality
Source sentences
Summary
In GLP-1 receptor agonist-treated patients, all-cause mortality, cardiovascular mortality, and myocardial infarction were significantly lower than in comparators (MH-OR [95% CI] 0.88 [0.79-0.97], p=0.015, 0.84 [0.74-0.96], p=0.009, and 0.90 [0.80-1.00], p=0.050, respectively), whereas no beneficial…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2850135201
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) lowered cardiovascular mortality versus comparators.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, were linked to fewer cardiovascular deaths than comparators.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular mortality
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist comparators
Outcome group
Mortality · Cardiovascular
Measurements
MH-OR
0.84 ratio
cardiovascular mortality
Source sentences
Summary
In GLP-1 receptor agonist-treated patients, all-cause mortality, cardiovascular mortality, and myocardial infarction were significantly lower than in comparators (MH-OR [95% CI] 0.88 [0.79-0.97], p=0.015, 0.84 [0.74-0.96], p=0.009, and 0.90 [0.80-1.00], p=0.050, respectively), whereas no beneficial…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2850135202
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) lowered overall myocardial infarction versus comparators.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, were linked to fewer heart attacks than comparators.
Peptide
Semaglutide
Outcome
DecreaseMyocardial infarction
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist comparators
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.9 ratio
myocardial infarction
Source sentences
Summary
In GLP-1 receptor agonist-treated patients, all-cause mortality, cardiovascular mortality, and myocardial infarction were significantly lower than in comparators (MH-OR [95% CI] 0.88 [0.79-0.97], p=0.015, 0.84 [0.74-0.96], p=0.009, and 0.90 [0.80-1.00], p=0.050, respectively), whereas no beneficial…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2850135203
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) showed no significant effect on stroke versus comparators.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, showed no clear effect on stroke compared with comparators.
Peptide
Semaglutide
Outcome
No significant changeStroke
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist comparators
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
whereas no beneficial effect was observed for stroke and heart failure (MH-OR [95% CI] 0.90 [0.81-1.00]. p=0.059.
2 context sentences(design, population, supporting numbers)
Summary · context
0.89 [0.76-1.04]. p=0.15. and 0.92 [0.81-1.06]. p=0.25. respectively).
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2850135204
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) showed no significant effect on heart failure versus comparators.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, showed no clear effect on heart failure compared with comparators.
Peptide
Semaglutide
Outcome
No significant changeHeart failure
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist comparators
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
whereas no beneficial effect was observed for stroke and heart failure (MH-OR [95% CI] 0.90 [0.81-1.00]. p=0.059.
2 context sentences(design, population, supporting numbers)
Summary · context
0.89 [0.76-1.04]. p=0.15. and 0.92 [0.81-1.06]. p=0.25. respectively).
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2850135205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 37 to 40Current
28 Oct 2026, 02:04 UTC
The same notice was added 4 times, first on 27 Oct 2026, 18:19 UTC. The status did not change between them.
Study results updated
Version 36
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Versions 34 to 35
22 Oct 2026, 02:26 UTC
The same notice was added 2 times, first on 22 Oct 2026, 02:25 UTC. The status did not change between them.
Study results updated
Version 33
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Versions 3 to 32
21 Oct 2026, 17:06 UTC
The same notice was added 30 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.

Summary

Results from this study5

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms

Keywords